Non-steroidal anti-inflammatory drugs and the chemoprevention of colorectal and oesophageal cancers

In recent years, several areas of biological research have increasingly supported the suggestion that aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the occurrence or progression of colorectal and, to a lesser extent, oesophageal cancer or both. This suggestion is supported by consistent biochemical, pharmacological, toxicological, clinical, and epidemiological messages. This leading article reviews the evidence and demonstrates how these diverse studies can be translated into strategies for NSAID intervention trials in cohorts at risk of colorectal and oesophageal cancer.

**NSAIDs and colorectal cancer**

In 1977, Bennett et al. noted increased concentrations of prostaglandins in colorectal cancer tissue when compared with normal colorectal mucosa. Given the pharmacological ability of NSAIDs to inhibit the cyclooxygenase (COX-1) enzyme and thereby block prostaglandin synthesis, several research groups (notably Pollard and Luckett and Narisawa et al.) soon considered the effects of NSAIDs on chemically induced cancers in rodents. Landmark studies then showed that NSAIDs could both prevent and reverse colorectal adenomas and carcinomas. Since then more than 20 studies have been published and nearly all have confirmed the original reports. Indeed, the chemopreventive properties of several NSAIDs including aspirin, indomethacin, sulindac, and sulindac have been shown.

Clinical experience with NSAIDs included a series of case reports and randomised trials, which demonstrated the ability of sulindac to reduce the size and number of colorectal polyps occurring in patients with familial adenomatous polyposis (FAP). These findings have important public health implications as it is likely that the adenoma/carcinoma sequence in FAP patients is similar to that of the general population. This concept is supported by recent epidemiological findings of a 40%–50% reduction in mortality from colorectal cancer among subjects regularly taking NSAIDs compared with those not taking these agents. Two further clinical trials designed to test screening and antioxidant strategies for colorectal cancer have found decreased risks of colorectal adenomas among regular aspirin users.

None of these studies have provided information regarding optimum dose and frequency of aspirin use. To obtain data that can be translated into intervention strategies, future epidemiological studies should consider the relations between aspirin consumption, baseline cancer risk, and the resultant adenoma/carcinoma incidence.

Although these independent lines of research all support the link between NSAID use and colorectal cancer, the pharmacological basis of NSAID protection remains unclear. Protection is probably multifactorial and could be related to the ability of NSAIDs to arrest colorectal carcinogenesis at several stages. In low-moderate risk patients, the ability of NSAIDs to augment tumour immunosurveillance mechanisms may be sufficient to prevent cancer while in moderate-risk patients, NSAIDs may arrest carcinogenesis directly within the colorectal mucosa. There is a biochemical basis for this suggestion because the colorectal mucosa metabolises arachidonic acid predominantly via a lipoxygenase pathway to form leukotrienes. The colorectal mucosa is thus associated with a low prostaglandin/leukotriene ratio, however, colorectal carcinogenesis is associated with progressive increases in mucosal prostaglandin E2 synthesis. NSAIDs may arrest this carcinogenic stage by inhibiting prostaglandin E2 synthesis and diverting the arachidonic acid cascade into lipoxygenase metabolism. Biochemically, this would parallel a restoration of the low prostaglandin/leukotriene ratio. In medium-high risk patients, NSAIDs may arrest carcinogenesis using a combination of these properties. Furthermore, there are indications that NSAIDs stimulate programmed cell death (apoptosis) in vitro and in FAP patients. Rodent models of colorectal cancer provide good experimental models to examine the effects of NSAIDs upon apoptosis. In high risk carcinoma in situ patients, NSAIDs may prevent or retard (chemoprecrastination) the development of spreading cancer by augmenting tumoricidal colorectal immunosurveillance mechanisms. This tumoricidal property may be related to the inhibition of immunosuppressive/carcinostimulant prostaglandin E2, which is produced in excessive amounts by a colorectal cyclooxygenase (COX-2) enzyme that can be induced by various mitogens including cell growth factors, cytokines, and tumour promoters.

COX-2 inhibitors are attractive chemopreventive targets because selective inhibition may prevent cancer while avoiding the complications of bleeding and gastric irritation. These explanations emphasise the need to develop an evidence-based dose related carcinogenic grading system as it is probable that low-moderate risk patients will require lower and less frequent NSAID dosing than high risk patients. Indeed, the profiling of these arbitrary risk levels challenges the validity of the epidemiological studies because it is extremely difficult to retrospectively grade baseline cancer risk levels in large populations. Furthermore, the definitions of regular aspirin use have varied between studies. Hence, the variables of cancer risk and aspirin dose/frequency have no consistent correlation and a 40%–50% risk reduction may reflect a net result of varying degrees of protection. For example, regular aspirin consumption in low-moderate risk, moderate-medium risk, medium-high risk, and high to carcinoma in situ cohorts could be associated with risk reductions of 80%, 60%, 40%, and 20% respectively. In accordance with this principle, the American Cancer Society have called for randomised trials directed at the prevention of colorectal adenomas as precursors of colorectal cancer.

**NSAIDs and oesophageal cancer**

The evidence supporting a link between NSAID use and oesophageal cancer is less clear. Epidemiological studies have mainly focused on the development of esophageal cancer due to the anti-inflammatory properties of NSAID-derived agents. Clinical trials have demonstrated the ability of NSAIDs to reduce the frequency of oesophageal polyps in patients with familial adenomatous polyposis (FAP). However, the relationship between NSAID use and oesophageal cancer is complicated by the fact that the majority of patients with oesophageal cancer are smokers, and smoking is a well-recognised risk factor for oesophageal cancer. Moreover, the risk of oesophageal cancer increases with age, and NSAID use is also associated with age. In addition, the risk of oesophageal cancer is lower in patients with a history of NSAID use, and this trend is more pronounced in patients with a history of aspirin use.

Leading articles express the views of the author and not those of the editor and the editorial board.
Oesophageal cancer is less strong. There are, however, similarities between the carcinogenic process and the chemopreventive potential of NSAIDs in these organs (Table). Oesophageal cancer is also associated with the excessive production of prostaglandin E2 and two published reports have documented the ability of NSAIDs to prevent and reverse chemically induced oesophageal cancers in rodents.32 33 Epidemiological studies, however, have produced conflicting results. Thun et al34 studied 635 031 adults who, in 1982, had provided information on the frequency and duration of their aspirin use. They found a 40%--50% reduction in oesophageal cancer risk among regular aspirin users. A similar, albeit smaller (12 668 subjects) study by Schreinemacher and Everson35 found that aspirin consumption offered no protection against oesophageal cancer. Both studies reported an inverse correlation between aspirin consumption and colorectal cancer risk. There are, however, good pharmacological reasons to suspect that regular NSAID consumption does offer protection against oesophageal squamous cell carcinoma and adenocarcinoma. Chronic oesophagitis, an important precancerous oesophageal lesion and inflammation, is associated with the excessive mucosal production of prostaglandin E2.36 The raised prostaglandin/leukotriene ratio may contribute to carcinogenesis because prostaglandin E2 seems to be carcinostimulant in the oesophagus whereas lipoxygenase metabolities are protective.37 NSAIDs can prevent and reverse oesophageal inflammation, and biochemically this would parallel a restoration of the low prostaglandin/leukotriene ratio associated with the normal oesophageal mucosa. NSAID intervention may be particularly useful in the areas of the world with a high incidence of chronic oesophagitis and oesophageal squamous cell carcinoma.

Barrett’s oesophagus is an important precancerous lesion and is thought to represent an adaptive response to longstanding reflux injury. Barrett’s oesophagus may be prevented by NSAIDs because prostaglandin E2 seems to drive the cycle of dysmotility, duodenogastric reflux, mucosal injury, aggravated dysmotility, and further duodenogastric reflux.36 37 The incidence of Barrett’s related adenocarcinoma has increased recently. This may be related to a ‘Western’ diet rich in prostaglandin E2 precursors such as linoleic acid. High values of prostaglandin E2 can relax the pyloric and cardiac sphincters while suppressing gastric acid secretion (A M Sammon, personal communication) and the resulting non-acid duodenogastric reflux may initiate or exacerbate the vicious prostaglandin E2 cycle. Furthermore, the immunostimulatory properties of NSAIDs may be valuable as Barrett’s oesophagus is associated with the depressed function of tumoricidal immune cells.38 NSAIDs could help to prevent malignant degeneration in Barrett’s patients by augmenting tumoricidal mechanisms. This property may be related to the inhibition of immunosuppressive prostaglandin E2 synthesis.

Objections to NSAID intervention
Because of the major public health and economic implications of NSAID cancer chemoprevention, it is essential that all recommendations are evidence based. NSAIDs can damage the gastrointestinal tract, liver, and kidneys and thus the potential benefit would need to be balanced against the risk of adverse effects. For cardiovascular disease aspirin chemoprevention with an optimum dose of 160 mg daily has been associated with a favourable benefit versus risk ratio. This does not, however, justify large scale aspirin chemoprevention because the doses of aspirin required for cancer protection may be greater than the antiplatelet dose.39 In the absence of an evidence dose related carcinogenic grading system, caution is required because biased messages reaching the general public may be misinterpreted. For example, advocating the benefit of aspirin without highlighting potential risk may lead to the inappropriate or excessive consumption. A multidisciplinary scientific approach is therefore required to produce evidence based guidelines before chemoprevention strategies can be implemented.

In high-risk cohorts where NSAID chemoprevention trials appear justifiable, additional measures could be used to reduce the risk of NSAID toxicity. This could include the use of enteric coated aspirin, NSAIDs with excellent safety profiles such as azapropazone, or, in high risk patients, the use of selective COX-2 inhibitors such as nabumetone.40-42 Furthermore, in high risk patients requiring high or frequent doses of NSAIDs, omeprazole administration could be considered as there are reports that acidic NSAIDs can exacerbate oesophageal and colorectal inflammation.43 44 Omeprazole can prevent NSAID gastroduodenal toxicity45 and this property justifies the serious consideration of an NSAID chemoprevention study in patients with Barrett’s oesophagus.

NSAIDs and Barrett’s oesophagus
Although omeprazole is often used in the treatment of Barrett’s oesophagus the effects on adenocarcinoma risk are unclear. Regression of Barrett’s oesophagus has been reported46 while others believe that omeprazole may encourage adenocarcinoma by facilitating alkaline reflux.47 Patients with Barrett’s oesophagus receiving omeprazole are good candidates for NSAID chemoprevention as a number of carcinogenic biomarkers could be monitored. These include immune status and the prostaglandin/leukotriene ratios in both the Barrett’s and squamous mucosas. NSAIDs may also provide clinical benefit by arresting the underlying reflux cycle while the restoration of the low prostaglandin/leukotriene ratio associated with the squamous mucosa may encourage columnar cell regression. Barrett’s oesophagus is associated with increased risks of colorectal cancer48 49 and this supports the rationale for NSAID chemoprevention. Randomised controlled trials of omeprazole/NSAID versus omeprazole/placebo are therefore warranted. The NSAID sulindac would be a good choice for such trials given its success in FAP patients.

Future research
Future research programmes should assess the effects of NSAIDs upon intermediate carcinogenic markers such as immune status and prostaglandin/leukotriene ratios. Patients with FAP and Barrett’s oesophagus are good...
candidates for NSAID or placebo randomised controlled trials. A carcinogenic grading system for oesophageal and colorectal cancer should define individual or population cancer risks, or both, as low, moderate, medium or high. Such a grading system should be versatile to accommodate regional risk factors, such as traditional dietary practices, and could be scored by assessing factors such as alcohol intake, age, demographies, dietary habits, genetic predisposition, and the presence or severity of precancerous lesions. The advantage of a quantifiable system is that NSAID efficacy could be monitored as a function of baseline risk, while changes in cancer risk may require proportionate increases or decreases in NSAID dosage and frequency. In anticipation of this, future epidemiological studies should consider the relation between aspirin consumption, baseline cancer risk, and resultant cancer incidence. Data from these studies will support the design of a dose related carcinogenic grading system. The design of this system will require a multi-disciplinary/multi-national approach, however, it would herald a break through in cancer prevention because evidence based NSAID intervention strategies could be implemented.

GARETH MORGAN
Pharmaceutical Department,
West Glamorgan Health Authority,
41 High Street,
Swansea SA1 1LT

Addendum

Three relevant papers have been recently published. In an epidemiological study, Finkhouser and Sharp noted that aspirin use decreased the risk of fatal oesophageal carcinoma by 90%. Cauvin et al. found that 25% of Barrett’s oesophagus patients had colorectal adenomas. These patients are excellent candidates for sulindac/omeprazole studies.

Finally, NSAIDs may also be useful in the treatment of oesophageal carcinoma.1 Tumorigenic NSAIDs may induce carcinoma regression and could also help to reduce the risk of side effects from radiotherapy and surgery.
